MIST - Milestone Pharmaceuticals Inc.
After hours:
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 4.1000 |
| Open | 4.0400 |
| Bid | 3.9000 x 3000 |
| Ask | 4.3600 x 2200 |
| Day's Range | 3.9300 - 4.0900 |
| 52 Week Range | 3.1000 - 9.8470 |
| Volume | |
| Avg. Volume | 113,196 |
| Market Cap | 132.764M |
| Beta (5Y Monthly) | 2.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3000 |
| Earnings Date | Aug 08, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
Fair Value
Related Research
CNW GroupMilestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced promising data from an ad hoc analysis of a subset of patients experiencing atrial fibrillation with rapid ventricular rate (AFib-RVR) in the NODE-303 study, which evaluated etripamil, the Company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT). The data were f
PR NewswireMilestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2023, and provided a clinical and corporate update.
- PR Newswire
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Monday, May 22, 2023 at 8:00 a.m. ET. The event will focus on etripamil, the Company's lead investigational product, for the potential treatment of patients with atrial fibrillation (AFib) and rapid ventricular rate (AFib-RVR).
Simply Wall St.Lorenz Muller Is The Chief Commercial Officer of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) And They Just Picked Up 23% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Milestone Pharmaceuticals Inc. ( NASDAQ:MIST...
- Simply Wall St.
Milestone Pharmaceuticals' (NASDAQ:MIST) investors will be pleased with their decent 75% return over the last three years
One simple way to benefit from the stock market is to buy an index fund. But if you buy good businesses at attractive...
- CNW Group
Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023 at 3:45 p.m. ET.
- Simply Wall St.
Despite recent gains, Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insiders are still down US$91k after purchasing last year
Insiders who bought US$355k worth of Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ) stock in the last year recovered...
- PR Newswire
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a clinical and corporate update.
- PR Newswire
Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has entered into a $125 million strategic funding agreement with existing shareholder, RTW Investments, LP and certain of its affiliates ("RTW"). Proceeds from this tailored financing, together with $64.6 million of cash, cash equivalents and short-term investments as of December 31, 2022, are expected to fund
- CNW Group
Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced significant progress in clinical and regulatory activities for etripamil, the Company's investigational calcium channel blocker that is administered by patients outside of the healthcare setting to treat paroxysmal supraventricular tachycardia (PSVT).
- CNW Group
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will present at the following investor conferences:
ZacksMilestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Simply Wall St.
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is definitely on the radar of institutional investors who own 33% of the company
If you want to know who really controls Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ), then you'll have to look at the...
ZacksHere's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks
The heavy selling pressure might have exhausted for Milestone Pharmaceuticals (MIST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- Simply Wall St.
Will Milestone Pharmaceuticals (NASDAQ:MIST) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- PR Newswire
Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of the Company's management team will host a virtual commercial deep-dive event on Tuesday, December 6, 2022 at 1:00 p.m. ET. The event will focus on the commercial opportunity for etripamil, the Company's lead investigational product, for the treatment of patients with paroxysmal supraventricular tachycar
- PR Newswire
Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 1:30 p.m. ET in New York, NY.
- Simply Wall St.
Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have unfortunately lost 74% over the last three years
Every investor on earth makes bad calls sometimes. But really big losses can really drag down an overall portfolio. So...
- CNW Group
Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2022, and provided a clinical and corporate update.
- CNW Group
Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the presentation of new data from the Phase 3 RAPID clinical trial of etripamil, the Company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting. The presentation, titled "Self-administered Etripamil for Termination of Spontaneous Paroxysmal
- PR Newswire
Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that data from the Phase 3 RAPID clinical trial of self-administered etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting will be featured during a Late-Breaking Clinical Trials session at the American Heart Association Scientific Sessions 2022 taking place November 5-7, 2022
- Simply Wall St.
Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) recent US$101m market cap decline means a loss of US$6.2k for insiders who bought this year
Insiders who acquired US$308k worth of Milestone Pharmaceuticals Inc.'s ( NASDAQ:MIST ) stock at an average price of...
- Simply Wall St.
Independent Non-Executive Director Michael Tomsicek Just Bought A Handful Of Shares In Milestone Pharmaceuticals Inc. (NASDAQ:MIST)
Even if it's not a huge purchase, we think it was good to see that Michael Tomsicek, the Independent Non-Executive...
ZacksHere's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 42.9% in 4 Weeks
Milestone Pharmaceuticals (MIST) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ZacksMilestone's (MIST) Tachycardia Study Data Fail to Impress Investors
Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to impress investors.